Agios Q2 FY26 net loss narrows to $100.7 million; revenue more than doubles to $44.75 million
Reuters2026/07/30 10:35- Agios posted a GAAP net loss of $100.7 million, narrowing from $112 million a year earlier.
- GAAP revenue more than doubled to $44.7 million, driven by mitapivat (PYRUKYND and AQVESME) worldwide net revenue of $44.7 million.
- R&D expenses rose to $100.8 million due to a $25 million upfront payment to license cevidoplenib; SG&A climbed to $51.5 million.
- Cash, cash equivalents and marketable securities fell to $964.8 million as of June 30, 2026, from $1.16 billion at end-2025.
- Mitapivat sNDA won FDA Priority Review in sickle cell disease with a Nov. 1, 2026 PDUFA date; AQVESME reached 442 cumulative U.S. thalassemia prescriptions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marcopolo board member cuts stake by R$ 19,194.97 in open-market share sale
Yelp Integrates OpenAI's Conversational Voice Model Into Business Tools
Mentor Walsh and legendary trader Druckenmiller closed-door meeting: US interest rates are too low, dovish stance is absurd, AI may have a profit bubble
Druckenmiller, who was a long-term mentor to former U.S. Treasury Secretary Paul Volcker and Federal Reserve Chairman Alan Greenspan, stated that there is "no longer a need" for the Federal Reserve to cut interest rates. He characterized the recent sustained increase in yields as "a slow, fundamentally driven rise." Regarding AI, he commented: "We are likely in a profit bubble, as this AI craze will eventually come to an end," and revealed that he has reduced his AI-related holdings to 20% of what they were six months ago.
Hawthorn Bancshares director Jonathan “Jon” Holtaway dies at 55
Crypto prices
More
